Search

Ο Δρ. Κωνσταντίνος Βουγάς εξηγεί πως η πρωτεΐνη ακίδα των εμβολίων κατά του Covid εξασθενεί τους αμυντικούς μηχανισμούς του οργανισμού και τον εκθέτει σε σοβαρό κίνδυνο ανάπτυξης καρκινωμάτων Ο Δρ. Κωνσταντίνος Βουγάς είναι πτυχιούχος Μοριακής Βιολογίας από το Πανεπιστήμιο του Πόρτσμουθ, Ηνωμένο Βασίλειο και διδάκτορας της Ιατρικής Σχολής του Πανεπιστημίου Αθηνών. Είναι ο Διευθύνων Σύμβουλος και Διευθύνων Σύμβουλος της DeepMed και επίσης είναι ο Κύριος Ερευνητής (Επίπεδο Αναπληρωτή Καθηγητή) της Βασικής Μονάδας Πρωτεωμικής του Ιδρύματος Βιοϊατρικών Ερευνών της Ακαδημίας Αθηνών από το 2015. #Covid19 #Vaccines #HealthResearch

New finding: Raynaud’s phenomenon may be more than an isolated vascular response to cold. In patients with early Raynaud’s, the coexistence of capillaroscopic abnormalities and autoantibodies - particularly ANA and anti-Scl-70 - was associated with higher mortality during https://t.co/7jR0ZEEQ7Y #RaynaudsPhenomenon #Autoimmunity #HealthResearch #Therearenospecificcountrycodesmentionedinthetweetprovided.

This is such an important thread! A massive new study provides more evidence for what has been known for decades: vaginal estradiol can greatly help with recurrent UTIs and reduce their potentially deadly complications like sepsis. https://t.co/l7vfy60nWO #VaginalEstradiol #RecurrentUTIs #HealthResearch #Nospecificcountrycodesarementionedinthetweet.

Impressive study suggesting that hyperglycosylation (addition of sugars to proteins) may be a driver of Alzheimer’s disease 👀 They also show that glucosamine supplements (often used for joint health) are associated with Alzheimer’s progression and mortality. #Alzheimers #HealthResearch #Glucosamine #Therearenospecificcountriesmentionedinthetweet.

Rare diseases may each affect few patients, but together they impact millions of families across 🇪🇺. We must strengthen awareness, research & cooperation. European Reference Networks connect expertise across Member States. The EU has invested €3.2bn in rare disease research. ⤵️ #RareDiseases #HealthResearch #EURareDiseases #EU

A new daily pill called orforglipron may help individuals who stop using injectable weight loss medications maintain their weight loss, as a study shows that those taking the pill retained over 70% of their lost weight after a year, compared to 38-50% for the placebo group, with further research needed to determine the long-term effects of the treatment. #WeightLoss #ObesityTreatment #HealthResearch #US #GB

A new daily pill, orforglipron, has shown promise in helping individuals maintain weight loss after stopping injectable weight loss medications, with study participants who took the pill retaining over 70% of their weight loss, while those on a placebo maintained only 38-50%, suggesting a potential shift in obesity treatment methods. #WeightLoss #ObesityTreatment #HealthResearch #US #GB

A new pill called orforglipron may help prevent weight regain in individuals who have stopped using weight loss injections, with research indicating that those taking it daily for a year maintained over 70% of their initial weight loss, and its potential for broader availability following approval in the U.S. and possibly the U.K. soon. #WeightLoss #ObesityTreatment #HealthResearch #US #GB

A new daily pill, orforglipron, may help individuals maintain weight loss after discontinuing injectable weight loss medications, according to a study published in Nature Medicine, which found that participants taking the pill preserved over 70% of their weight loss compared to 38-50% in the placebo group, suggesting that oral medication could offer a more appealing alternative to injections for long-term obesity management. #WeightLoss #ObesityTreatment #HealthResearch #US #UK

A new pill named orforglipron may help individuals who have stopped using weight-loss injections maintain their weight loss, as a study showed that participants taking the pill daily for a year effectively prevented weight regain, while also improving health markers related to obesity, though further research is needed to determine the long-term effects and optimal duration of treatment. #WeightLoss #ObesityTreatment #HealthResearch #US #GB

A new pill called orforglipron may help individuals who stop using weight loss injections maintain their weight loss, with a study showing that those taking the pill for a year significantly prevented weight gain after discontinuing GLP-1 injections, although further research is needed to determine its long-term usage and effects. #ObesityManagement #WeightLoss #HealthResearch #US #GB

A new daily pill called orforglipron may help individuals maintain weight loss after stopping GLP-1 injections, with recent trials showing that it allowed participants to retain over 70% of their weight loss, suggesting a promising alternative to injectable treatments. #WeightLoss #ObesityTreatment #HealthResearch #US #UK

A new daily pill called orforglipron shows promise in helping people maintain weight loss after discontinuing weight-loss injections, with trial results indicating that participants who took the pill retained more than 70% of their lost weight, suggesting a potential long-term treatment option for obesity, although further research is needed to understand the durability of its effects. #WeightLoss #ObesityTreatment #HealthResearch #US #UK

A new daily pill called orforglipron may help individuals transitioning off weight-loss injections maintain their weight loss, as a study found that those taking the pill maintained over 70% of their weight loss after one year compared to only 38-50% in the placebo group, with the drug expected to be more accessible than current injectable treatments. #WeightLoss #ObesityManagement #HealthResearch #US #UK

A new daily pill called orforglipron has shown promise in helping people maintain their weight loss after discontinuing GLP-1 injections, with a study revealing that participants taking the drug retained over 70% of their weight loss after a year, compared to 38-50% in the placebo group, while also potentially reducing long-term health risks associated with obesity, although further research on the duration of treatment is needed. #WeightLoss #ObesityTreatment #HealthResearch #US #UK

A new daily pill called orforglipron has been found to help individuals maintain their weight loss after discontinuing weight-loss injections, showing promising results in trials, while offering a potentially more convenient alternative to injections, and highlighting the need for ongoing treatment in managing obesity. #WeightLoss #ObesityManagement #HealthResearch #US #UK

A new daily pill called orforglipron may help individuals maintain weight loss after stopping GLP-1 injections, with trials showing that participants who took the pill retained over 70% of their weight loss compared to 38-50% for those on a placebo, although further research is needed to determine the long-term effects and potential need for lifelong treatment. #WeightLoss #ObesityTreatment #HealthResearch #US #UK

Recent research indicates that a new daily oral medication called orforglipron may help individuals who have lost weight through injections maintain their weight loss, with trial participants retaining over 70% of their weight loss compared to 38-50% in a placebo group, while also showing favorable effects on blood pressure, lipids, and blood glucose. #WeightLoss #ObesityTreatment #HealthResearch #US #UK